glp 1 breast cancer GLP-1 Receptor Agonists Linked to Improved Survival Outcomes in Frontiers | GLP-1 receptor agonist

This pilot study suggest that the nasal drops may be used as an alternative to injections because two thirds of ME/CFS patients reported a positive effect, accompanied by an increased number of steps, improvement of the RAND-36 physical functioning scale and the CIS20r fatigue scale, and a significant increase in serum vitamin B12 levels

REV.09.25

61 A working core outcome set for CLE trials was recently developed to guide future clinical and outcomes research in CLE, recommending the CLASI as a primary endpoint and the Cutaneous Lupus Activity IGA (CLA-IGA) as a secondary endpoint for CLE physician-reported outcome measures

Ree, R., Varland, S., & Arnesen, T